Metformin–Transition Metal Complexes for Mitochondrial Weight Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-obesity and diabetes medications have severe adverse effects and lack interventions targeting the intestine-brain axis, specifically the hypothalamus, which is the homeostatic center for appetite regulation, and there is a need for new pharmaceuticals with peripheral action mechanisms and minimal side effects.
Innovation Solution
Development of metformin complexes with transition metals such as iron (II), cobalt (II), nickel (II), copper (II), zinc (II), and bismuth (III) that target the mitochondria for therapeutic effects on diabetes, obesity, and related conditions, offering crystalline forms with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current anti-obesity pharmaceuticals (such as Sibutramine, Rimonabant, Orlistat) are used, then appetite reduction and weight loss effects are achieved, but severe adverse effects occur (neurological side effects, gastrointestinal problems)
Solution Approach 1:
The patent introduces metformin-transition metal complexes as intermediary compounds that mediate the therapeutic effect. These complexes act as carriers that deliver the active metformin molecule to specific targets (mitochondria, intestine-brain axis) while the transition metal component (Fe, Co, Ni, Cu, Zn, Bi) provides additional biological activity and reduces adverse effects through synergistic mechanisms.
Solution Approach 2:
The patent changes the chemical and biological parameters of metformin by forming coordination complexes with transition metals. This transformation alters the pharmacokinetic properties, target specificity, and mechanism of action, converting a peripheral drug into a multi-targeting agent that acts on mitochondria and the intestine-brain axis simultaneously, thereby improving weight loss efficiency while reducing adverse effects.
2Reliability
If metformin is used as a peripheral drug, then safety and effectiveness are improved, but lack of intervention on the intestine-brain axis limits its therapeutic potential for obesity
Solution Approach 1:
The patent makes metformin multi-functional by incorporating it into transition metal complexes that can simultaneously target multiple systems: the mitochondria for metabolic regulation, the intestine-brain axis for appetite control, and peripheral tissues for weight loss. This universal complex structure enables a single compound to address multiple therapeutic needs while maintaining the safety profile of metformin.
Solution Approach 2:
The transition metal complex acts as an intermediary that bridges the gap between peripheral action and central nervous system modulation. The complex carries metformin to both peripheral mitochondria and, through metal-ion mediated mechanisms, to the intestine-brain axis, thereby extending therapeutic potential while preserving safety.
3Productivity
If transition metal complexes are developed to target mitochondria, then efficiency in weight reduction is improved, but complexity of compound structure increases
Solution Approach 1:
The patent creates composite pharmaceutical compounds by combining metformin with transition metal ions (Fe, Co, Ni, Cu, Zn, Bi) to form coordination complexes. These composite structures leverage the synergistic properties of both components: metformin provides metabolic regulation and safety, while the transition metals contribute to mitochondrial targeting, weight reduction efficiency, and potential neuroprotective effects.
Solution Approach 2:
The patent applies local quality by directing the complexed metformin to specific biological targets with different functions. The transition metal complex structure enables localized action at the mitochondria for metabolic efficiency, while also providing targeted intervention at the intestine-brain axis for appetite regulation, thereby achieving high weight reduction efficiency through spatially-specific biological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The metformin-transition metal complexes demonstrate higher efficiency in weight reduction and lower side effects by targeting the energetic core of the organism, providing effective treatment for diabetes, obesity, and related diseases with minimal adverse reactions.
Implementation Method 1
The new compounds of the invention, by having a therapeutic effect on a cellular level, specifically in the mitochondria, attack the energetic core of the organism leading to higher efficiency in weight reduction
Data Source
AI summary
Disclosed herein is an invention that refers to hydrochloride metformin complexes with transition metals and group P elements, such as cobalt (II), nickel (II), copper (II), zinc (III), iron (II), bismuth (III) and their preparation method. Additionally, the present invention offers crystalline forms of the metformin-cobalt (II) complex, metformin-nickel complex and metformin-copper complex as well as methods for therapeutic use in patient treatment and their preparation method.